Review of ADSC-Exos for diabetic foot ulcers lacks reported efficacy data or safety outcomes in this narrative synthesis

This narrative review examines the potential application of adipose-derived stem cell exosomes for treating diabetic foot ulcers and managing diabetes. The scope of the article focuses on these specific conditions without detailing the underlying clinical trials or observational studies that may have informed the discussion.

The authors indicate that critical methodological information was not reported. Specific data points such as the study population, sample size, intervention dosing, and primary outcomes are absent from the provided text. Because these details are missing, the review cannot quantify the clinical benefit or risk associated with this intervention.

Safety and tolerability profiles were also not reported in the source document. The authors do not provide specific adverse event rates or discontinuation data. Without these numbers, clinicians cannot assess the risk-benefit balance for patients considering this therapy.

The practice relevance remains unclear due to the lack of quantitative evidence. Readers should interpret this review as a qualitative overview rather than a source of definitive clinical guidance for diabetic foot ulcer management.